BioAge Labs
BIOA

BioAge Labs (BIOA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$40.00Aug 6, 2026
BTIGMaintainedBuy$40.00Aug 3, 2026
NeedhamMaintainedBuy$35.00 from $50.00Jul 31, 2026
Roth CapitalInitiated CoverageBuy$36.00May 27, 2026
BTIGInitiated CoverageBuy$40.00May 13, 2026
NeedhamInitiated CoverageBuy$50.00Mar 27, 2026
CitigroupMaintainedBuy$52.00 from $15.00Mar 10, 2026
OppenheimerInitiated CoverageOutperform$60.00Feb 25, 2026
JefferiesUpgradedHold → Buy$62.00 from $9.00Feb 18, 2026
Piper SandlerInitiated CoverageOverweight$73.00Jan 27, 2026
Morgan StanleyUpgradedUnderweight → Equal-Weight$12.00 from $5.00Dec 8, 2025
CitigroupMaintainedBuy$15.00 from $10.00Oct 29, 2025
CitigroupUpgradedNeutral → Buy$10.00 from $5.00Oct 22, 2025
CitigroupMaintainedNeutral$5.00 from $7.00Mar 24, 2025
Morgan StanleyInitiated CoverageUnderweight$5.00Mar 7, 2025
William BlairInitiated CoverageMarket PerformFeb 28, 2025
JefferiesDowngradedBuy → Hold$7.00 from $42.00Dec 9, 2024
CitigroupDowngradedBuy → Neutral$7.00 from $45.00Dec 9, 2024
CitigroupInitiated CoverageBuy$45.00Oct 21, 2024
JefferiesInitiated CoverageBuy$42.00Oct 21, 2024

Frequently asked questions

  • What is the latest analyst rating on BIOA?

    On Aug 6, 2026, BTIG maintained BioAge Labs at Buy with a price target of $40.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.